Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elenestinib Monotherapy and Combination in Advanced Systemic Mastocytosis
NCT05609942Phase 1Terminated
- Sponsor
- Blueprint Medicines
- Start
- Sep 2023
- Primary completion
- Jan 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 1, open-label trial of elenestinib in systemic mastocytosis (SM) (2 arms), sponsored by Blueprint Medicines. Primary endpoints: Number of Dose-limiting Toxicities (Monotherapy) at 28 Days, Number of Dose-limiting Toxicities (Combination) at 28 Days and 3 more. Started Sep 2023; status: terminated.
02
Drugs
elenestinib
03
Conditions
systemic mastocytosis (SM)
Beyond the preview
Go deeper on NCT05609942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05609942.